| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697922 | Clinical Oncology | 2016 | 10 Pages |
Abstract
A validation of the disease control rate and the overall response rate as a surrogate end point of survival at a patient level and a standardised definition of the timing for their measurement are strongly recommended in trials of chemotherapy plus bevacizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
G. Colloca, A. Venturino, D. Guarneri,